IVVD News

In the typically-slow month of August, nine IPOs raised $1.0 billion, joined by 31 SPACs. Only four of the nine offerings raised over $100 million. Activity was well below August 2020, which saw investors and bankers skip their vacations due to the pandemic. Five listings also postponed this past month amid poor IPO aftermarket returns and “IPO indigestion” after summer...read more

Adagio Therapeutics, a Phase 2/3 biotech developing antibody therapies to treat and prevent COVID-19, raised $309 million by offering 18.2 million shares at $17, within the range of $16 to $18. The company offered 0.5 million more shares than anticipated. Adagio Therapeutics' lead program, ADG20, is being developed for the treatment and prevention of SARS-CoV-2 and its variants....read more

Adagio Therapeutics, a Phase 2/3 biotech developing antibody therapies for COVID-19 and other infectious diseases, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $301 million by offering 17.7 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Adagio Therapeutics would command a fully diluted market value of...read more

Adagio Therapeutics, a Phase 1 biotech developing antibody therapies COVID-19 and other infectious diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Adagio Therapeutics' lead program, ADG20, has completed enrollment in a Phase 1 clinical trial for the treatment of SARS-CoV-2 and its variants. The company claims that unlike other...read more